More than 1 million prescriptions for the COVID-19 antiviral pills Lagevrio and Paxlovid were dispensed between late December 2021 and May 2022, but dispensing rates were lowest in the most socially and economically disadvantaged communities, according to a study released today by the Centers for Disease Control and Prevention. In a separate study of electronic health records from Kaiser Permanente Southern California over the period, fewer than 1% of patients aged 12 and older who received Paxlovid to treat mild-to-moderate COVID-19 had a COVID-19-related hospitalization or emergency department visit in the next five to 15 days. CDC said the studies “highlight the importance of ensuring access to oral antiviral medicine in treating COVID-19, a key strategy in preventing hospitalization and death.”

Related News Articles

Perspective
One important learning from the two-and-a-half-year COVID-19 pandemic is that the public health emergency (PHE) waivers made an enormous difference for…
Headline
Children infected with COVID-19 are at higher risk afterwards for certain symptoms or conditions, according to a study released today by the Centers for…
Headline
As directed by President Biden in April, the Department of Health and Human Services today released a national plan for researching the long-term effects…
Blog
It’s been a tough two-and-a-half years. Many hospitals and health systems are struggling to ensure the safety of their staff, get the right supplies and find…
Headline
Inpatient and outpatient prospective payment system hospitals, inpatient psychiatric facilities and PPS-exempt cancer hospitals have until Aug. 30 to preview…
Chairperson's File
Remaining resilient as new variants of COVID-19 spread. Launching mobile health services to help ensure equitable distribution of COVID-19 vaccines. Partnering…